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Background.  The liver fluke Opisthorchis viverrini, highly prevalent in Southeast Asia, is an important public health bur-
den, including a risk factor for developing an aggressive bile duct cancer, cholangiocarcinoma, in chronically infected patients. 
Praziquantel, administered at a single 40 mg/kg dose in preventive chemotherapy programs and 3 × 25 mg/kg for individual treat-
ment, is the drug of choice, yet information on the nature of the dose-response relationship is lacking.
Methods. We performed a randomized, parallel, single-blind dose-ranging phase 2 trial in the Lao People’s Democratic Republic 
in O. viverrini–infected adults. Patients were randomly assigned to 30 mg/kg, 40 mg/kg, 50 mg/kg, or 3 × 25 mg/kg praziquantel or pla-
cebo. Adverse events were recorded at baseline, 3 hours, and 24 hours posttreatment. Cure rates (CRs) and egg reduction rates (ERRs) 
were estimated 3 weeks after drug administration using available case analysis. Dose-response curves were predicted using Emax models.
Results. Two-hundred seventeen O. viverrini–infected patients were assigned to the 5 treatment arms. The majority (94.3%) 
of patients harbored light infections. The Emax model predicted a high efficacy among the observed dose range. We observed CRs 
ranging from 92.7% to 95.5% and ERRs >99.5% for all praziquantel treatment groups. Adverse events were mild but higher in the 
standard treatment group (3 × 25 mg/kg) than in the single-dose treatment arms.
Conclusions. Single-dose praziquantel appears to be as efficacious as the standard 3 × 25 mg/kg regimen for the treatment of O. viver-
rini infections, while presenting fewer adverse events. Further studies are necessary in moderate and heavy O. viverrini infections.
Clinical Trials Registration. Randomized Controlled Trials (ISRCTN77186750).
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The trematode Opisthorchis viverrini is a significant pub-
lic health problem in Southeast Asia. Opisthorchiasis affects 
>8 million people, primarily around the lower Mekong 
basin in Thailand, Lao People’s Democratic Republic (PDR), 
Cambodia, and Vietnam [1]. This foodborne trematodiasis is 
acquired by the consumption of raw, fermented, or marinated 
fish dishes, harboring O. viverrini metacercariae [2–5]. Due 
to its location in the bile ducts, the parasite causes chronic 
inflammation of the biliary epithelium, leading to cholangi-
ocyte hyperplasia and periductal fibrosis [6, 7]. Periductal 
fibrosis predisposes individuals to develop ascending chol-
angitis. The chronic inflammation and oncogenic properties 
associated with prolonged O. viverrini infection also predis-
poses individuals to develop cholangiocarcinoma, a malignant 
bile duct cancer that occurs in about 10% of infected individ-
uals [8, 9].
The standard treatment for O.  viverrini is praziquantel, a 
broad-spectrum anthelmintic pyrazino-isoquinoline, effec-
tive against almost all flatworm species [10]. The standard 
dosing scheme to treat opisthorchiasis is 3 time-separated 
doses of 25  mg/kg body weight administered orally within 
24 hours for 2 consecutive days [11, 12]. In morbidity con-
trol programs, a single dose of 40 mg/kg is commonly used 
[12]. The Lao national recommendation is to use either a 
single 40  mg/kg or 75  mg/kg divided in 3 doses for 1  day 
[13]. Dose-response relation studies of praziquantel with 
opisthorchiasis patients are, however, lacking, which might 
simplify and optimize the administration strategy for 
large-scale deworming campaigns. Three dose-compari-
son studies were performed in Thailand in the early 1980s 
among adults with opisthorchiasis. The first trial compared 
a 3  ×  25  mg/kg treatment schedule administered in 1  day 
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compared to a 6  ×  25  mg/kg schedule given over 2  days, 
both of which yielded a high cure rate (CR) of 100% [14]. 
The second study focused on lower doses of 1 ×  25  mg/kg, 
2 × 25 mg/kg, and 40 mg/kg and observed CRs of 44%, 89%, 
and 91%, respectively [15]. In the third trial, doses of 40 mg/kg 
and 50 mg/kg were investigated, resulting in CRs of 96% and 
97%, respectively [16]. In a recent trial in Lao PDR compar-
ing doses of 40  mg/kg and 50  +  25  mg/kg in infected chil-
dren, the observed CRs were 71% and 97%, respectively [17]. 
However, none of the trials investigated the effect of single 
oral doses compared with the standard triple 25 mg/kg dose 
in a homogenous trial design. Determining whether—and 
which—single oral doses are equivalent to triple dosing could 
have important implications both for individual therapy as 
well as preventive chemotherapy campaigns.
The aim of this study is to determine the nature of the dose-re-
sponse relationship of praziquantel in the treatment of opist-
horchiasis in adult patients using single oral doses of 30 mg/kg, 
40 mg/kg, and 50 mg/kg, with placebo and the standard dose of 
3 × 25 mg/kg as comparators.
METHODS
Setting and Participants
The study was conducted between August and October 2014 in 
2 villages (Maisivilay and Namsaitha) of Champasack province, 
southern Lao PDR, an area that is highly endemic for O. viver-
rini infection [18, 19].
We included all patients between 15 and 76 years of age with 
a diagnosed O. viverrini infection, not suffering from major sys-
temic, acute, and/or chronic illnesses or psychiatric and neurologi-
cal disorders. In addition, we excluded patients who were pregnant 
or had an anthelmintic treatment within the last 3 months.
The study was approved by the National Ethics Committee 
for Health Research, Ministry of Health of Lao PDR (refer-
ence no. 033/2014) and the Ethics Committee of Northern and 
Central Switzerland (reference no. 163/2014) The study is reg-
istered at Randomized Controlled Trials (ISRCTN77186750).
Randomization and Blinding
Using a computerized block randomization procedure (varia-
ble block size of 5 and 10), we assigned participants to different 
dosages of praziquantel (30, 40, 50 mg/kg or 3 × 25 mg/kg) or 
placebo. Praziquantel (Distocide; 600 mg) was purchased from 
Shin Poong, Korea. Placebo tablets of similar shape and color 
were purchased from Fagron, Germany. Tablets were adminis-
tered in 150-mg increments. For the 3 × 25 mg/kg treatment, 
each praziquantel dose was administered in 4-hour intervals. 
Participants, investigators, and laboratory technicians were 
blinded to group assignment. The investigator responsible for 
treatment might have been aware of the dose due to the num-
ber of tablets administered, but he was not involved in adverse 
events (AEs) or parasitological assessment. The blinding was 
maintained throughout the trial until data entry and processing 
were completed and the data had been verified.
Procedures
We invited village inhabitants to join an information meeting 
in Lao language about the objectives, procedures, potential 
risks, and benefits of the study. Potential participants were 
given adequate information about the research process by the 
local co–principal investigator and trained health personnel 
and were allowed to ask questions. Following the meeting, eli-
gible villagers were invited to participate and written informed 
consent was obtained from each study participant. In case of 
illiteracy of the villagers, the informed consent was presented 
orally. Two stool samples were collected from each participant 
within a maximum of 5 days and analyzed using the Kato-
Katz method [20] and the quantitative formalin-ether con-
centration technique (FECT) [21] for the detection of minute 
intestinal flukes, such as Haplorchis taichui and Phaneropsolus 
bonnei [22, 23]. Two Kato-Katz thick smears (41.7 mg) were 
prepared from each stool sample and exactly 1 g of stool was 
preserved in 10% of formalin for the FECT analysis, follow-
ing the methods used by Sayasone and colleagues [24]. The 
duplicate Kato-Katz thick smears were examined under a light 
microscope by 2 different experienced technicians. Ten per-
cent of the negative slides were randomly chosen for quality 
control reexamination.
Study participants with parasitologically confirmed O. viver-
rini infection underwent a full clinical examination to assess the 
presence of any acute and chronic diseases. Height (using a meas-
uring stick to the nearest point 1 cm), weight (using an electronic 
balance to the nearest 1 kg), blood pressure (using a sphygmo-
manometer to the nearest 0.1 mmHg), and axillary temperature 
(using battery-powered thermometers to the nearest 0.1°C) were 
recorded. A urine sample was collected from female participants 
for pregnancy testing (Orchid+, www.truelinemed.com). Before 
treatment, participants obtained a local meal (rice with vegeta-
bles). Study participants were observed for 3 hours following 
treatment (following the first dose in the 3 × 25 mg/kg group) by 
the physician team for documentation of possible AEs. For partic-
ipants reporting any symptoms, the study physicians performed 
a full clinical examination and, if needed, patients were treated 
accordingly. For the occurrence of AEs at 24 hours posttreatment 
(post–first dosing for the 3 × 25 mg/kg patients), patients were 
interviewed by home visits and followed up at 48 hours by phone 
interviews (results not shown). At 19–25 days posttreatment, 
another 2 stool samples were collected for assessing treatment 
efficacy. Study participants testing positive for intestinal parasites 
were treated according to national guidelines [13].
Outcome and Sample Size Determination
CR, defined as the conversion from a positive diagnostic Kato-
Katz test pretreatment to a negative test posttreatment, was the 
primary endpoint in our study. A previous dose range trial [25] 
showed that 40 individuals per group would result in a median 
precision (defined as one-half length of the 95% confidence inter-
val [CI]) of the dose-response curve of 5–10 percentage points.
Statistical Analysis
Data were digitally collected on tablets using CommCare ODK, 
version 2.8. The questionnaires and forms were developed in 
the CommCare server (www.commcarehq.org). A hard copy of 
the forms was also completed during the data collection and 
was used to cross-check 10% of the electronically collected 
data. Validated data were transferred to Stata software, version 
14 (StataCorp, College Station, Texas), and R (R Foundation for 
Statistical Computing, Vienna, Austria) version 3.2.4, for statis-
tical analyses.
Infection intensity, expressed as eggs per gram of stool 
(EPG), was determined for each individual by adding egg 
counts of the 4 examined Kato-Katz smears and multiply-
ing by 6. Opisthorchis viverrini infections were classified into 
low (1–999 EPG), moderate (1000–9999 EPG), and heavy 
(≥10 000 EPG) infection intensities [26]. Egg reduction rates 
(ERRs) were determined based on arithmetic and geometric 
mean egg counts. The arithmetic ERR is the relative difference 
expressed as percentage between the posttreatment mean egg 
count and the pretreatment mean egg count (1– post mean 
egg count/pre mean egg count) including all patients. For the 
geometric mean ERR, a log transformation log (x + 1) was 
first calculated prior to determining the relative difference, 
expressed in percentage between the posttreatment mean egg 
count and the pretreatment mean egg count. Ordinary nonpar-
ametric bootstrap resampling within each trial group (2000 rep-
licates) was used to determine 95% CIs for the ERRs.
We performed an available case analysis including all patients 
with primary endpoint data. An intention-to-treat (ITT) anal-
ysis is presented in Supplementary Table 1. For the ITT analy-
sis, 2 approaches were conducted to impute missing data—that 
is, all treatment success (all individuals with no endpoint data 
were assumed to be free of infection) and all treatment failure 
scenarios (all individuals with no endpoint data were assumed 
to have the same egg counts as before infection).
We evaluated dose-response curves by fitting nonlinear Emax 
models for CRs and ERRs for the placebo, 30 mg/kg, 40 mg/kg, 
and 50 mg/kg groups. For ERRs, we separately modeled pop-
ulation arithmetic and geometric mean reductions, using the 
DoseFinding package in R [27]. For individual ERRs, we mod-
eled residual egg proportion (final egg count/initial egg count) 
using a Tweedie compound Poisson-gamma distribution, an 
exponential dispersion model with a positive mass at zero. We 
used the Tweedie package [28] for maximum likelihood esti-
mation of the index parameter and Statmod package [29] for 
Tweedie Family generalized linear model, and then predicted 
individual egg reduction as a function of dose.
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primary endpoint in our study. A previous dose range trial [25] 
showed that 40 individuals per group would result in a median 
precision (defined as one-half length of the 95% confidence inter-
val [CI]) of the dose-response curve of 5–10 percentage points.
Statistical Analysis
Data were digitally collected on tablets using CommCare ODK, 
version 2.8. The questionnaires and forms were developed in 
the CommCare server (www.commcarehq.org). A hard copy of 
the forms was also completed during the data collection and 
was used to cross-check 10% of the electronically collected 
data. Validated data were transferred to Stata software, version 
14 (StataCorp, College Station, Texas), and R (R Foundation for 
Statistical Computing, Vienna, Austria) version 3.2.4, for statis-
tical analyses.
Infection intensity, expressed as eggs per gram of stool 
(EPG), was determined for each individual by adding egg 
counts of the 4 examined Kato-Katz smears and multiply-
ing by 6. Opisthorchis viverrini infections were classified into 
low (1–999 EPG), moderate (1000–9999 EPG), and heavy 
(≥10 000 EPG) infection intensities [26]. Egg reduction rates 
(ERRs) were determined based on arithmetic and geometric 
mean egg counts. The arithmetic ERR is the relative difference 
expressed as percentage between the posttreatment mean egg 
count and the pretreatment mean egg count (1– post mean 
egg count/pre mean egg count) including all patients. For the 
geometric mean ERR, a log transformation log (x + 1) was 
first calculated prior to determining the relative difference, 
expressed in percentage between the posttreatment mean egg 
count and the pretreatment mean egg count. Ordinary nonpar-
ametric bootstrap resampling within each trial group (2000 rep-
licates) was used to determine 95% CIs for the ERRs.
We performed an available case analysis including all patients 
with primary endpoint data. An intention-to-treat (ITT) anal-
ysis is presented in Supplementary Table 1. For the ITT analy-
sis, 2 approaches were conducted to impute missing data—that 
is, all treatment success (all individuals with no endpoint data 
were assumed to be free of infection) and all treatment failure 
scenarios (all individuals with no endpoint data were assumed 
to have the same egg counts as before infection).
We evaluated dose-response curves by fitting nonlinear Emax 
models for CRs and ERRs for the placebo, 30 mg/kg, 40 mg/kg, 
and 50 mg/kg groups. For ERRs, we separately modeled pop-
ulation arithmetic and geometric mean reductions, using the 
DoseFinding package in R [27]. For individual ERRs, we mod-
eled residual egg proportion (final egg count/initial egg count) 
using a Tweedie compound Poisson-gamma distribution, an 
exponential dispersion model with a positive mass at zero. We 
used the Tweedie package [28] for maximum likelihood esti-
mation of the index parameter and Statmod package [29] for 
Tweedie Family generalized linear model, and then predicted 
individual egg reduction as a function of dose.
RESULTS
Participant Flow and Baseline Characteristics
The study flowchart is presented in Figure 1. We recruited 634 
adults, of whom 21 did not consent to follow the trial. An O. 
viverrini infection was diagnosed in 231 patients of the 443 
patients who provided 2 stool samples, and no minute intestinal 
flukes were observed, as confirmed by FECT analysis. Fourteen 
patients were excluded from the trials due to chronic diseases 
(ie, chronic cardiovascular, diabetes, chronic kidney failure, and 
chronic hepatitis). In total, 217 participants were assigned to 
the 5 treatment arms. Five patients were absent at the follow-up 
examination (2.3% loss), and 1 patient from the 40 mg/kg 
treatment group was wrongly dosed receiving a 54 mg/kg dose. 
Table 1 summarizes the demographic and parasitological base-
line characteristics. Baseline O. viverrini infection intensity, 
coinfection with other helminths, sex, age, weight, and height 
were well balanced among treatment groups. More than 90% 
of the patients harbored a light infection (median EPG in study 
arms ranging from 54 to 78).
Efficacy of Praziquantel
The range of the actual mean doses administered were 
28–33, 39–42 (plus the wrongly dosed patient at 54  mg/kg) 
and 49–65  mg/kg praziquantel in the single-dose 30  mg/kg, 
40 mg/kg, and 50 mg/kg groups, and triple doses of 23–33 mg/kg 
praziquantel in the 3 × 25 mg/kg group.
The Emax model predicted a high efficacy in terms of on 
CRs (Figure 2) and ERRs based on geometric means (Figure 
3) among the observed dose range. There was no indication 
that higher single doses or a triple-dose regimen improves 
the efficacy markedly. Similarly high CRs were observed for 
all praziquantel treatment groups (92.7%–95.5%). For the 
placebo treatment, we observed a CR of 29.3% (Table 2). The 
corresponding ERRs for the treated groups were 99.5%–99.7% 
based on geometric mean and 94.7%–98.9% based on arithme-
tic mean. ERRs of placebo were 70.1% (geometric mean) and 
–8.6% (arithmetic mean).
Adverse Events
Before treatment, 34.9% of the patients treated with prazi-
quantel and 28.6% of the placebo group reported mild clinical 
symptoms, such as vertigo or headache (Table 3). Three hours 
posttreatment, the placebo-treated group displayed a similar 
number of mild AEs (26.2%) compared with the baseline levels, 
with only 1 patient with moderate symptoms. In the praziquan-
tel-treated groups, a total of 54.9% and 13.1% of the patients 
suffered from mild and moderate AEs, respectively. The most 
common AEs among praziquantel-treated patients were mild 
vertigo (53.8%; Table  4), mild headache (22.2%), and mild 
nausea (17.0%). The highest numbers of mild vertigo events 
were observed in the 40 mg/kg and 50 mg/kg treatment groups 
(62.2% and 61.4%, respectively).
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Twenty-four hours posttreatment, a higher number of 
patients treated with the triple praziquantel dose compared with 
single doses reported mild (45.2% vs 22.7%–31.8%) and mod-
erate (16.7% vs 0–2.3%) AEs (Table 3). Placebo-treated patients 
revealed a low number of mild AEs (7.1%) 24 hours posttreat-
ment. The most common reported AE 24 hours posttreatment 
was mild vertigo (22.8% of all praziquantel-treated patients), 
which was mainly observed among participants assigned to the 
standard triple dose (48%) (Table 4).
DISCUSSION
Praziquantel has been widely used for several decades for the 
treatment of infections with the liver flukes O. viverrini, O. feli-
neus, and Clonorchis sinensis. Apart from triclabendazole, used 
Table 1. Baseline Characteristics of Opisthorchis viverrini–Infected Patients Stratified by Treatment Group
Placebo (n = 41)
Praziquantel
Characteristic
30 mg/kg
(n = 41)
40 mg/kg
(n = 45)
50 mg/kg
(n = 44)
3 × 25 mg/kg
(n = 41)
Female sex, % 43.9 51.2 46.7 47.7 53.7
Age, y, median (IQR) 44 (31–56) 45 (30–55) 43 (29–53) 48 (33–57) 47 (35–59)
Weight, kg, median (IQR) 57 (50–65) 55 (51–62) 59 (53–65) 55 (50–60) 57 (50–61)
Height, cm, median (IQR) 160 (155–163) 159 (152–165) 159 (155–164) 159 (152–161) 158 (150–162)
EPG, median (IQR) 60 (27–198) 54 (30–240) 54 (18–144) 75 (30–176) 78 (21–207)
Opisthorchis viverrini infection intensity, % (No.)
 Low 95.1 (39) 92.7 (38) 93.3 (42) 95.4 (42) 95.1 (39)
 Moderate 4.9 (2) 7.3 (3) 6.7 (3) 4.6 (2) 4.9 (2)
 Heavy 0 0 0 0 0
Coinfections, % (No.)
 Hookworms 56.1 (23) 53.7 (22) 71.1 (32) 50.0 (22) 61.0 (25)
 Taenia species 9.8 (4) 12.2 (5) 15.6 (7) 11.4 (5) 4.9 (2)
 Trichuris trichiura 0 4.9 (2) 0 4.6 (2) 0
 Ascaris lumbricoides 0 0 0 2.3 (1) 0
Abbreviations: EPG, eggs per gram; IQR, interquartile range.
Figure 1. Trial profile.
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for the treatment of infections with Fasciola species [30], prazi-
quantel is the mainstay for the treatment of most foodborne 
trematode infections. In 2015, an estimated 600 000 individuals 
were reported to be treated for foodborne trematodiases world-
wide [31]. However, proper dose-response relationship studies 
have not been conducted to date, which is reflected into the 
various dosing strategies currently applied. Our study aimed to 
close this knowledge gap and inform treatment recommenda-
tions as well as preventive chemotherapy guidelines.
All doses of praziquantel used in our study were highly 
effective, showing a flat dose-response curve and achieving 
similar CRs of 93–95%. Hence, our study is not able to define a 
no-effect dose range. Our findings are in contrast to an earlier 
study [15], which guided the selection of the doses used in 
our study. This trial in Thailand reported a complete cure of 
all the patients treated with 3 × 25 mg/kg, while a low CR of 
44% was detected for a single 25 mg/kg praziquantel dose. 
In a nearby setting, in southern Laos PDR, CRs were 96.6% 
after 50 + 25 mg/kg praziquantel and 71.4% after a single 40 
mg/kg dose of praziquantel in O. viverrini–infected children, 
as observed by Lovis and colleagues [17]. The high efficacy 
observed in the present study, with doses as low as 30–40 mg/
kg could be explained with the low infection intensities of 
patients, in contrast to Thai participants who suffered from 
moderate to high infection intensities [15]. The relationship 
between praziquantel efficacy and infection intensities (ie, 
Figure 2. Emax model for the cure rates (CRs) of placebo and 4 doses of praziquantel against Opisthorchis viverrini infections. Circles show observed CRs with 95% confidence 
intervals (CIs; vertical lines). The solid line represent the estimated dose-response curve and the dashed lines the corresponding 95% CIs predicted by the Emax models.
Figure 3. Emax model for egg reduction rates (ERRs) of placebo and 4 doses of praziquantel against Opisthorchis viverrini infections based on population geometric means. 
Circles show observed cure rates with 95% confidence intervals (CIs; vertical lines). The solid line represent the estimated dose-response curve and the dashed lines the 
corresponding 95% CIs predicted by the Emax models. Abbreviations: EPG, eggs per gram.
Downloaded from https://academic.oup.com/cid/article-abstract/64/4/451/2623956/Efficacy-and-Safety-of-Praziquantel-Against-Light
by WWZ Bibliothek (Oeffentliche Bibliotherk der UniversitÃ¤t Basel) user
on 09 October 2017
456 • CID 2017:64 (15 February) • Sayasone et al
higher CRs among patients with low infection intensities) has 
been described for the treatment of Schistosoma patients [32, 
33]. However, in the study by Lovis and colleagues, patients 
harboring light infection intensities demonstrated only a 
moderate CR of 75% [17]. Another explanation could be the 
influence of food administered with the treatment [34, 35]. 
Lovis et al provided a single spoon of rice together with the 
medication, while in our study the patients received a break-
fast prior to treatment, which most likely increased bioavail-
ability and consequently efficacy. It has been well studied that 
the administration of food increases maximum plasma levels 
of praziquantel [36]. In the other studies, no information on 
concomitant food was reported. The relatively important CRs 
observed in the placebo group (29.3%) can be explained by 
the light infection intensities observed among our patients, 
which play with the limits of detection of microscopic 
diagnostics.
Our study was unable to discriminate the effect of escalating 
treatment dosages and a triple dose on ERRs estimated based 
on geometric means. However, calculating mean individual 
ERRs brings out a different result, with noticeable differences 
between treatment arms (Supplementary Figure  1). A  model 
of individual ERRs displays a higher variability in ERRs and 
a lower mean ERR among the 30  mg/kg group compared to 
the other doses (Supplementary Figures 2 and 3) that could be 
translated into a more important outcome difference among 
patients harboring high infection intensities. To be noted, in 
the 30  mg/kg group, there was 1 patient with a tremendous 
increase in egg burden (>600%), which is weighting on the 
mean individual-based ERRs.
Table 3. Clinical Symptoms Observed Prior to Treatment and 3 and 24 Hours After Treatment With Different Praziquantel Dosages Against Opisthorchis 
viverrini Infectionsa
Observed Symptoms Placebo (n = 41)
Praziquantel
30 mg/kg
(n = 41)
40 mg/kg
(n = 45)
50 mg/kg
(n = 44)
3 × 25 mg/kgb
(n = 41)
Overall
(N = 171)
Before treatment
 None 71.4 (30) 75.0 (33) 57.8 (26) 70.5 (31) 57.1 (24) 65.1 (114)
 Mild 28.6 (12) 25.0 (11) 42.2 (19) 29.5 (13) 42.9 (18) 34.9 (61)
 Moderate 0 0 0 0 0 0
3 h posttreatment
 None 71.4 (30) 36.4 (16) 20.0 (9) 22.7 (10) 50.0 (21) 32.0 (56)
 Mild 26.2 (11) 54.6 (24) 60.0 (27) 61.4 (27) 42.9 (18) 54.9 (96)
 Moderate 2.4 (1) 9.0 (4) 20.0 (9) 15.9 (7) 7.1 (3) 13.1 (23)
24 h posttreatment
 None 92.9 (39) 75.0 (33) 77.8 (35) 68.2 (30) 38.1 (16) 65.1 (114)
 Mild 7.1 (3) 22.7 (10) 22.2 (10) 31.8 (14) 45.2 (19) 30.3 (53)
 Moderate 0 2.3 (1) 0 0 16.7 (7) 4.6 (8)
aData are shown as percentage (No.).
bThe first dose is the reference time for adverse event reporting.
Table 2. Cure and Egg Reduction Rates of Different Praziquantel Dosages Against Opisthorchis viverrini Infections
Efficacy Measure Placebo (n = 41)
Praziquantel
30 mg/kg
(n = 41)
40 mg/kg
(n = 45)
50 mg/kg
(n = 44)
3 × 25 mg/kg
(n = 41)
CR
 Patients positive before treat-
ment, No.
41 41 45 44 41
 Patients positive after treatment, 
No. (%)
29 (70.7) 3 (7.3) 3 (6.7) 2 (4.5) 3 (7.3)
 CR, % (95% CI) 29.3 (16.1–45.5) 92.7 (80.0–98.5) 93.3 (81.7–98.6) 95.5 (81.3–98.6) 92.7 (80.0–98.5)
Geometric mean EPG
  Before treatment 77.0 80.2 70.6 72.4 65.4
  After treatment 23.0 0.4 0.2 0.2 0.3
  ERR, % (95% CI) 70.1 (41.9–85.3) 99.5 (98.4–100.0) 99.7 (99.0–100.0) 99.7 (99.3–100.0) 99.5 (98.8–100.0)
Arithmetic mean EPG
  Before treatment 227.9 257.6 336.4 172.8 230.5
  After treatment 247.5 13.6 3.6 2.3 4.2
  ERR, % (95% CI) –8.6 (–110.5 to 38.2) 94.7 (83.7–99.5) 98.9 (93.6–99.8) 98.7 (95.4–99.5) 98.2 (90.7–99.7)
Abbreviations: CI, confidence interval; CR, cure rate; ERR, egg reduction rate; EPG, eggs per gram.
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Three hours after treatment, slightly more than half of the 
patients reported mild AEs, but no differences between dosages 
could be identified. This observation highlights that treatment 
with praziquantel, even at low doses, is inherently followed by 
mild AEs. At 24 hours, the triple standard dose seemed to have 
affected the patients more than following single doses, with a 
higher number of patients complaining about symptoms. The 
most frequent AE reported at 3 hours and 24 hours was vertigo. 
This is consistent with other trials in opisthorchiasis patients, 
where dizziness and headache were the most prominent symp-
toms [16, 36–38]. In studies involving schistosomiasis patients, 
on the other hand, the treatment is first associated with gas-
trointestinal problems [32, 39, 40]. Abdominal signs in schis-
tosomiasis patients can be explained by the release of parasitic 
antigens in the mesenterial veins and liver, not only by dying 
worms but also by eggs, which hatch as a consequence of the 
treatment with praziquantel [41]. In opisthorchiasis patients, 
the immune reaction to parasitic antigens after treatment could 
in theory differ because of the parasite’s location in the bile 
ducts. To note, the various AEs reported in trials are also subject 
to cultural or genetic differences of the target patients.
In conclusion, our study provides convincing data that single 
doses of praziquantel reveal a similar performance compared 
to the standard 3 ×  25  mg/kg dose and were better tolerated 
over 24 hours posttreatment. Given the practicability of a sin-
gle-dose regimen, recommendations for individual patient 
management might be adopted. Our data support the use of the 
recommended dose of 40  mg/kg in preventive chemotherapy 
programs. However, as most patients harbored light O. viverrini 
infections, further studies are necessary in moderate and heavy 
O. viverrini infections.
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Table 4. Adverse Events Among Opisthorchis viverrini–Infected Patients Assessed 3 and 24 Hours After Treatment by Praziquantel Dosagea
Placebo (n = 41)
Praziquantel
30 mg/kg 
(n = 41)
40 mg/kg 
(n = 45)
50 mg/kg 
(n = 44)
3 × 25 mg/kgb 
(n = 41)
Overall 
(N = 171)
Adverse Event 3 h 24 h 3 h 24 h 3 h 24 h 3 h 24 h 3 h 24 h 3 h 24 h
Headache
 Mild 0 0 12.2 (5) 0 26.7 (12) 0 34.1 (15) 4.6 (2) 14.6 (6) 19.5 (8) 22.2 (38) 5.9 (10)
Nausea
 Mild 4.8 (2) 2.4 (1) 17.1 (7) 2.4 (1) 17.8 (8) 4.4 (2) 15.9 (7) 4.6 (2) 17.1 (7) 19.5 (8) 17.0 (29) 7.6 (13)
 Moderate 2.4 (1) 0 0 2.4 (1) 4.4 (2) 0 2.3 (1) 0 0 0 1.8 (3) 0
Vertigo
 Mild 24.4 (10) 2.4 (1) 46.3 (19) 9.8 (4) 62.2 (28) 13.3 (6) 61.4 (27) 20.5 (9) 43.9 (18) 48.8 (20) 53.8 (92) 22.8 (39)
 Moderate 0 0 4.9 (2) 0 8.9 (4) 0 6.8 (3) 0 2.4 (1) 4.9 (2) 5.9 (10) 1.2 (2)
Abdominal cramp
 Mild 0 0 4.9 (2) 2.4 (1) 6.7 (3) 2.2 (1) 0 2.3 (1) 0 4.9 (2) 2.9 (5) 2.9 (5)
Fatigue
 Mild 0 0 19.5 (8) 9.8 (4) 11.1 (5) 8.9 (4) 11.4 (5) 4.6 (2) 0 7.3 (3) 10.5 (18) 7.6 (13)
 Moderate 0 0 0 0 2.2 (1) 0 0 0 0 0 0.6 (1) 0
Allergy
 Mild pruritus without 
rash
0 0 0 0 2.2 (1) 0 0 0 0 0 0.6 (1) 0
 Mild localized urticaria 0 0 0 0 2.2 (1) 0 0 0 0 0 0.6 (1) 0
Vomitingc
 Mild 0 0 2.4 (1) 0 8.9 (4) 2.2 (1) 4.6 (2) 2.3 (1) 0 7.3 (3) 4.1 (7) 2.9 (5)
 Moderate 0 0 4.9 (2) 0 8.9 (4) 0 9.1 (4) 2.3 (1) 4.9 (2) 12.2 (5) 7.0 (12) 2.9 (5)
 Diarrhead
 Mild 2.4 (1) 0 0 2.4 (1) 2.2 (1) 2.2 (1) 6.8 (3) 0 2.4 (1) 7.3 (3) 2.9 (5) 3.5 (6)
aData are shown as percentage (No.).
bThe first dose is the reference time for adverse event reporting.
cVomiting: mild, 1 episode; moderate, 2–5 episodes in 24 hours; severe, >6 episodes or intravenous fluids required; critical, hospitalization.
dDiarrhea: mild, 3–4 episodes; moderate, 5–7 episodes; severe, >7 episodes or bloody diarrhea and intravenous fluids required; critical, hypotensive shock or hospitalization.
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